Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | CDC7 | O00311 | 1/20 | 0.33 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.33 |
| ▸ | CDK2 | P24941 | 1/20 | 0.33 |
| ▸ | DBF4 | Q9UBU7 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 2/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.31 |
| ▸ | CYP2A13 | Q16696 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31184838 | 0.76 | NOS3 (0.35) | KDM4EALDH1A1CYP2A6HTT | |
| SCHEMBL29952573 | 0.76 | NOS3 (0.35) | KDM4EALDH1A1CYP2A6HTT | |
| SCHEMBL28109131 | 0.75 | CCR1 (0.35) | GAAKDM4EALDH1A1 | |
| SCHEMBL31146149 | 0.75 | NR4A2 (0.32) | RAB9AGAAKDM4EALDH1A1HTT | |
| SCHEMBL8131114 | 0.74 | NOS2 (0.37) | CDK2ALDH1A1 | |
| SCHEMBL27348027 | 0.73 | RAB9A (0.32) | RAB9ACDC7CCNE1CDK2DBF4 | |
| SCHEMBL529516 | 0.72 | ALDH1A1 (0.38) | RAB9AGAAKDM4EALDH1A1 | |
| SCHEMBL30937638 | 0.72 | ALDH1A1 (0.38) | RAB9AGAAKDM4EALDH1A1 | |
| SCHEMBL16333419 | 0.70 | AURKA (0.40) | CDK2ALDH1A1CYP2A6 | |
| SCHEMBL16648947 | 0.69 | KDM4E (0.42) | RAB9ACDC7CCNE1CDK2DBF4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9458170-B2 | Compound of camptothecin and preparation and use thereof | YULIANG LI (CN) | 2016-10-04 | — | — | US | disclosed |
| US-9458170-B2 | Compound of camptothecin and preparation and use thereof | YULIANG LI (CN) | 2016-10-04 | — | — | US | disclosed |
| US-9458170-B2 | Compound of camptothecin and preparation and use thereof | YULIANG LI (CN) | 2016-10-04 | — | — | US | disclosed |
| US-20150166559-A1 | COMPOUND OF CAMPTOTHECIN AND PREPARATION AND USE THEREOF | Li, Yuliang (CN) | 2015-06-18 | — | — | US | disclosed |
| US-20150166559-A1 | COMPOUND OF CAMPTOTHECIN AND PREPARATION AND USE THEREOF | Li, Yuliang (CN) | 2015-06-18 | — | — | US | disclosed |
| US-20150166559-A1 | COMPOUND OF CAMPTOTHECIN AND PREPARATION AND USE THEREOF | Li, Yuliang (CN) | 2015-06-18 | — | — | US | disclosed |
| EP-2862571-A1 | COMPOUND OF CAMPTOTHECIN AND PREPARATION AND USE THEREOF | Li, Yuliang (MN) | 2015-04-22 | — | — | EP | disclosed |
| EP-2862571-A1 | COMPOUND OF CAMPTOTHECIN AND PREPARATION AND USE THEREOF | Li, Yuliang (MN) | 2015-04-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150166559-A1 | COMPOUND OF CAMPTOTHECIN AND PREPARATION AND USE THEREOF | TOP2A, TOP2B, TYMP | RAB9A 1269/4885CDC7 1180/4885CCNE1 199/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.